Further pharma price cuts in Hungary, with 348 medicines down average 8.3%

13 May 2007

In Hungary, the price of 348 medicines dropped an average of 8.3% effective May 1. According to the Ministry of Health, the continuous price reductions on the Hungarian pharmaceutical market are as a result of the Pharmaeconomic Act which was introduced in January (Marketletters passim).

In the case of 34 drugs the price reduction exceeded 20%, while 70 medicines saw their prices drop more than 10%. The changes affected antacids, anti-diabetics, antihypertensive and cardiovascular medicines, antibiotics, certain anti-inflammatory drugs and antidepressants.

First time drug spending kept under control since fall of Communism

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight